{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "THC",
  "name": "Tenet Healthcare Corporation New",
  "url": "https://orbyd.app/dossiers/THC/",
  "json_url": "https://orbyd.app/dossiers/THC.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Hospital margin-expansion narrative re-rated on the 2026-07-24 Q2 beat and $295M FY26 adjusted-EBITDA guidance raise (+17.3% that session), with nine target hikes inside ten days carrying price to a 52wk high of $262.13. The leg is intact but the calendar is empty until the ~2026-11-03 Q3 print, so what happens next is drift, sector flow, or a give-back of the 2026-07-24 gap.",
  "invalidation_trigger": "A daily close below $233 round-trips the 2026-07-24 guidance-raise gap (session level $233.54) and says the $295M FY26 EBITDA raise is no longer underwritten; secondary, any of the nine banks that raised targets 2026-07-24→2026-08-03 reversing, or a 2027 ACA headwind guided above the ~$250M cited for 2026.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "USPI carries large noncontrolling interests: consolidated adjusted EBITDA overstates economics available to THC shareholders — read the after-NCI free-cash-flow line.",
    "Revenue is policy-linked (ACA exchange mix, Medicaid supplemental and state directed payments); guidance can move on CMS or congressional action, not operations.",
    "Social-sentiment scrapes on the string 'THC' are dominated by cannabis chatter, not Tenet Healthcare — retail-mention counts on this ticker are unreliable."
  ],
  "body_markdown": "## Current Thesis\nThe narrative leg on offer is hospital margin expansion that keeps compounding *through* a policy shock rather than after it. Tenet absorbed the expiry of enhanced ACA premium tax credits — a headwind management sized at roughly $250M to 2026 earnings growth, with exchange enrollment expected down about 20% — and still printed Q2 2026 consolidated adjusted EBITDA of $1,304M, up 16.3% YoY on revenue of $5,628M (+6.8%). On 2026-07-24 the company raised the FY26 adjusted EBITDA range to $4,830–5,030M, a $295M lift at the midpoint, and the stock closed that session's move up 17.3% to $233.54. Nine sell-side target increases followed inside ten days. Price has since carried to $262.13 (2026-08-07), 0.2% under the 52-week high of $262.63, with RSI(14) at 80.9.\n\nWhat an investor is buying here is the second derivative: hospital-segment margin at 18.0% versus 15.6% a year earlier, admissions +2.3% same-facility, and a company converting that into buyback (7.02M shares for $1,360M year-to-date, plus a fresh $2.0B authorization) at 2.33x net leverage. What is absent is a scheduled event. Nothing on the corporate calendar forces a re-rating between now and the Q3 print, estimated ~2026-11-03.\n\n## Bull Case\n- **Q2 2026 (reported 2026-07-24): adjusted diluted EPS $6.12 vs $4.02 a year earlier, +52.2%.** Net income available to common was $826M ($9.84 per diluted share). The beat was operational, not a one-line tax or gain artifact.\n- **Hospital Operations adjusted EBITDA $762M, +22.3% YoY, at an 18.0% margin against 15.6% in Q2 2025.** Same-facility admissions +2.3%, adjusted admissions +2.6%. Acuity and cost control did the work while exchange admissions fell.\n- **FY26 guidance raised across every line on 2026-07-24:** revenue $21,900–22,500M, adjusted EBITDA $4,830–5,030M (+$295M midpoint), adjusted diluted EPS $20.30–21.69, adjusted free cash flow $2,725–3,025M (+$225M midpoint). Investing.com's summary of the same slide deck puts adjusted free cash flow after noncontrolling interests at $1,825–2,055M.\n- **Balance sheet is no longer the story it was:** cash $2,170M and net debt/adjusted EBITDA of 2.33x at Q2, against a company that spent the prior decade as a leveraged-equity proxy. The $2.0B incremental repurchase authorization is a standing bid the market can observe.\n- **Sell-side revision flow ran one direction between 2026-07-24 and 2026-08-03:** Barclays $271, TD Cowen $263, Morgan Stanley $274, RBC $283, UBS $308, Baird $280 (Neutral), Guggenheim $283, Truist $290, Wells Fargo $281. Nine banks moved, none cut.\n\n## Bear Case\n- **The ACA headwind is not finished; 2026 was the first year of it.** Enhanced premium tax credits lapsed at the end of 2025; Healthcare Dive reported Tenet sizing the 2026 earnings-growth hit at about $250M, and Becker's reported the company projecting a ~20% drop in exchange enrollment, with displaced exchange patients converting toward uninsured roughly one-for-one. Third-party estimates cited by Premier put sector revenue loss at $68.6B across 2026–2027. The 2027 setup is not guided.\n- **USPI, the high-margin half of the story, is running on price.** Ambulatory adjusted EBITDA of $542M grew 8.8% at a 39.0% margin, but same-facility surgical cases were **down 1.2%** with revenue per case up 6.3%. Volume is not carrying that segment.\n- **Positioning is stretched on the observables.** RSI(14) 80.9 at 2026-08-07; the last close of $262.13 sits above eight of the nine post-print targets and just under the lowest of them, TD Cowen's $263. Benzinga ran an overbought-screen piece naming the stock on 2026-07-29, and a \"how much you would have made in 15 years\" retrospective on 2026-08-07 — the coverage mix is shifting from estimate revisions toward general-interest attention.\n- **Consolidated EBITDA overstates shareholder economics.** USPI carries substantial noncontrolling interests; the gap between headline adjusted free cash flow and the after-NCI line is the number that matters for the buyback's durability.\n- **The next three months are event-free.** No confirmed company catalyst inside 30 days. A crowded, extended tape with no scheduled information is a tape that trades on sector flow.\n\n## Setup & Price Structure\nMeasured, as of the 2026-08-07 close: $262.13, versus a 52-week high of $262.63 (−0.2%), three-month return +37.7%, RSI(14) 80.9.\n\nThe structure is a single-day repricing, not a grind. The 2026-07-24 session gapped the stock +17.3% to $233.54 (market capitalisation quoted at $17.4B intraday that day), and price has extended from there without a visible retest. That gap day is the reference shelf: the guidance-raise re-rating lives entirely above it. A move back through it means the market has decided the $295M midpoint lift does not survive contact with 2027 exchange attrition.\n\nOn crowding, the observables rather than a verdict: nine target raises inside ten sessions; price above all but one of them; RSI above 80 for a stretch during which the 2026-07-29 overbought screen has so far not been predictive — the stock rose after it. The company itself is the identified large buyer (7.02M shares, $1,360M YTD through Q2, plus $2.0B authorised), which cuts against an issuance-into-strength reading. No 2026 insider dispositions surfaced in the filing record reviewed for this note;\n\n**Life-cycle: ACCELERATING.** Dated by the 2026-07-24 guidance raise, the 2026-07-24→2026-08-03 cluster of nine target increases, and a 52-week high set within the last two sessions. Attention is expanding, not thinning. The markers that would date a flip to SATURATED are already forming: the 2026-08-07 retrospective piece, the absence of any new estimate-revision catalyst before November, and price trading above the sell-side target band.\n\n## Catalyst Calendar (next 30 days)\n- **No confirmed Tenet-scheduled event between 2026-08-08 and 2026-09-07.** This is itself the setup: the re-rating has no scheduled follow-up.\n- **~2026-09-01 (est.) — Wells Fargo Healthcare Conference, Boston.** Tenet presented at the 2025 edition on 2025-09-03 and reaffirmed guidance there; participation in the 2026 event is not confirmed as of 2026-08-08. If management appears, the 2027 exchange-attrition framing is what gets asked.\n- **2026-11-01 — ACA open enrollment opens for plan year 2027.** Weekly marketplace signup data during that window is the first hard read on whether the ~20% enrollment decline extends or stabilises.\n- **~2026-11-03 (est.) — Q3 2026 results.** The print that carries the initial 2027 frame and tests whether the raised FY26 range holds at the top end.\n\n## What Would Change Our Mind\nThe structural break is loss of the 2026-07-24 gap. That session repriced the equity on a $295M guidance raise; a full round-trip through the $233.54 level says the market no longer underwrites the raise, and the specific gradeable condition is **a daily close below $233**. Secondary conditions, each independently observable: the target-revision flow reversing (any of the nine banks that raised between 2026-07-24 and 2026-08-03 cutting back), the ~2026-09-01 conference passing with no participation and no incremental 2027 disclosure while price stalls under the $262.63 high, or management quantifying a 2027 ACA headwind larger than the ~$250M cited for 2026.\n\nOn the other side, the read strengthens if USPI same-facility surgical cases turn positive from the −1.2% printed in Q2, or if the repurchase pace visibly accelerates against the $2.0B authorisation while leverage stays near 2.33x.\n\n## Correlation Notes\n- **Sector beta is high and same-day.** On 2026-07-24 UHS appeared alongside THC in the session's healthcare gainers list; the hospital complex (HCA, UHS, CYH, ARDT) trades the same policy variable.\n- **The shared variable is ACA exchange enrollment, not hospital operations.** HCA guided a 2026 adjusted EBITDA hit of $600–900M from the enhanced-subsidy lapse; Tenet cited roughly $250M to earnings growth. Any congressional movement on premium tax credits reprices the group together and would swamp company-level execution.\n- **Managed care sits on the other side of the same trade.** Enrollment attrition that raises hospital uninsured mix changes payer risk pools; the two groups do not reliably move together on policy headlines.\n- **Credit-sensitive.** At 2.33x net leverage and with a high-yield capital structure, the equity carries spread sensitivity that pure-equity screens miss.\n- **Low linkage to the AI/semiconductor complex.** The 2026-07-24 tape that carried the print also had crude down about 4% and a broad defensive-and-rate-sensitive rally, so part of the day's move was sector rotation rather than name-specific.",
  "first_seen": "2026-07-28",
  "last_analyzed": "2026-08-08T14:05:40+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}